Watch For GI Effects in Roflumilast Patients
May 2015
New data will help clarify when to use roflumilast (Daliresp) to prevent COPD exacerbations.
You may hear that roflumilast decreases hospitalizations due to COPD exacerbations by 25%. But this is a relative reduction. Let your team know that this works out to one fewer hospitalization for every 24 severe COPD patients on Daliresp for a year.
Continue to maximize bronchodilators and inhaled steroids first. Ensure that patients are using their inhalers properly and consistently.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote